Michael Thurn

Dr Michael Thurn has over two decades of experience in the life sciences and biotechnology industry, and has accumulated extensive knowledge in drug regulation, drug discovery, pre-clinical and clinical development across dermatology in Australia and the US. He has held various senior executive, managerial and board positions in listed and private companies. Dr Thurn has worked with the Therapeutic Goods Administration in Australia, led the clinical development of a topical acne treatment through to completion of Phase 2 clinical trial, and also led Spinifex Pharmaceuticals which was sold to Novartis in a $700m transaction.
Bio last updated 23 Feb 2019

Article Timeline

Access to our data for Michael Thurn is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Michael Thurn is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 28/06/19

1 year TSR5 year TSR
71stBotanix Pharmaceuticals70%28%
103rdResApp Health44%118%
411thStrategic Elements-16%-12%
498thCAQ Holdings-30%-30%
737thFamily Insights Group-67%0%
731 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Chief Operating Officer, Head of Australian Operations, Executive Director (since Feb 2019)
Year started and most recent title

Share Transactions

$56k Bought
$20k Bought
Total value as at the date of the transaction
Source: Morningstar


121st↑Botanix Pharmaceuticals$1.8m
132nd↑Family Insights Group$1.2m
133rd-CAQ Holdings$1.6m
135th↑Strategic Elements$1.1m
136th↑ResApp Health$999k
198 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer